EG 427 presents positive preclinical data on lead asset EG110A at International Continence Society meeting
EG 427 announces that Dr. Greg Sarek, VP Research will be presenting at the 3rd annual Next Generation Gene Therapy Vectors conference
EG 427 announces attendance to multiple upcoming conferences
EG 427 announces attendance to multiple upcoming conferences in Europe and US.
EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment.
EG 427 announces issuance of the first 2 patents in Europe and Japan protecting its first product EG110A.
EG 427 will be presenting at BioFuture2023-09-26
EG 427 to present at East/West Biopharm conference2023-09-18
EG 427 at International Continence Society 20232023-09-18
EG427 at BIO 20232023-09-18
Meet us at BIO €quity in Dublin2023-09-18
EG 427 will be presenting at BIO Europe Spring 20232023-02-07
See you at BioFIT 2022!2022-11-14
We'll be in BioFIT in Strasbourg on November 29-30, 2022. Our CEO, Philippe Chambon, will be presenting the company in the Startup Slam.
Come and meet us to learn more about nrHSV-1.
EG427 will be presenting at Bio-Europe Spring 20222022-11-04
Attend our presentation to know more about the company. Looking forward to e-meet you there!
Meet us at Cell Gene Med 2022 in Barcelona2022-11-04
Our CEO, Philippe Chambon MD, PhD will be presenting EG 427 and our gene therapy platform.